AZD9291の初回投与量漸増試験

基本情報

NCT ID

NCT01802632

ステータス

完了

試験のフェーズ

第1/第2相

試験タイプ

介入

目標被験者数

603

治験依頼者名

AstraZeneca

概要

This study will treat patients with advanced NSCLC who have already received at least one course of specific anti-cancer treatment but the tumour has started to re-grow following that treatment. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment, it will measure the levels of drug in the body, it will also measure the anti-cancer activity. By using these pieces of information together the best dose of this drug to use in further clinical trials will be selected.

対象疾患

介入

依頼者（Sponsor）